Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06722729
PHASE2

A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease

Sponsor: Kissei Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks in patients with advanced PD with levodopa.

Official title: A Late Phase II Clinical Trial of KDT-3594 in Patients With Advanced Parkinson's Disease With Levodopa

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2024-12-16

Completion Date

2026-04

Last Updated

2026-03-03

Healthy Volunteers

No

Interventions

DRUG

KDT-3594

Oral administration

DRUG

Placebo

Oral administration

Locations (1)

Research Site

Multiple Locations, Japan